2019/03/22 by Georg Hopfinger, Ulrich Jäger, Nina Worel · 1 citation
Medicine · Biochemistry, Genetics and Molecular Biology · Engineering · #CAR-T cell therapy research #Virus-based gene therapy research #Integrated Circuits and Semiconductor Failure Analysis #Medicine #Chimeric antigen receptor #Cytokine release syndrome #Lymphoma #Hematopoietic stem cell transplantation #Cell therapy #Clinical trial #Oncology #Transplantation #Immunotherapy #Adverse effect #Blinatumomab #Immunology #Internal medicine #Stem cell #CD19 #Antigen #Immune system #Biology
paper · doi:10.1097/hs9.0000000000000185
openalex publication_date 2019/03/22 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29
Patients with non-Hodgkin lymphomas (NHLs) resistant to standard therapies have a dismal prognosis. The outcome is even poorer in patients relapsing after autologous stem cell transplantation. Most of these patients do not qualify for an allogeneic hematopoietic cell transplantation (HCT) due to refractory disease, lack of a suitable allogeneic donor, higher age, or cumulative toxicity of previous chemotherapy. Despite patients undergoing allogeneic HCT normally profit from a graft-versus-lymphoma effect, overall survival in patients with NHL after HCT remains short. Therefore, novel treatment modalities are urgently needed. Chimeric antigen receptor (CAR)-T cells, a new class of cellular immunotherapy involving ex vivo genetic modification of T cells to incorporate an engineered CAR have been used in clinical trials. In the majority of studies, B cell malignancies treated with CD19 targeting CAR-T cells have been analyzed. Recently, results from 2 CD19 directed CAR-T cell trials with an increased follow-up of patients led to Food and Drug Administration and European Medicines Agency approval of tisagenlecleucel and axicabtagene ciloleucel. Common adverse events (AEs) include cytokine release syndrome and neurological toxicity, which may require admission to an intensive care unit, B cell aplasia and hemophagocytic lymphohistiocytosis. These AEs are manageable when treated by an appropriately trained team following established algorithm. In this review, we summarize the results of 3 large phase II CD19 CAR-T cell trials and focus on AEs. We also provide a perspective of ongoing activity in this field with the intend to improve the potency of this emerging novel therapy.